Every 10-Q that Senti Biosciences Holdings, Inc. (SNTI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SNTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNTI filings page.
Senti Biosciences Holdings, Inc., a clinical-stage cell and gene therapy company, reported a Q2 2026 net loss of $12.8 million, improving from $14.7 million a year earlier. For the first six months of 2026, net loss was $17.0 million versus $28.8 million in 2025 as research and development spending declined.
Cash and cash equivalents fell to $6.5 million at June 30, 2026 (total cash and restricted cash $7.9 million), down from $19.9 million at year-end, with $21.7 million used in operating activities in the first half. Total assets were $33.1 million against $36.5 million of liabilities, resulting in negative stockholders’ equity of $3.4 million. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern, noting it may be unable to maintain operations as early as Q4 2026 without additional funding.
Liquidity was supplemented by $10.0 million of senior secured convertible notes issued in May 2026 to a related-party affiliate of Celadon Partners, initially recorded at a $4.3 million fair value with a $5.7 million capital contribution. Subsequent to quarter-end, Senti agreed to a merger with a Celadon affiliate under which most of its existing business will be acquired, while current stockholders and certain other holders will receive contingent value rights of up to $60.0 million tied to future SENTI‑202 milestones.
Senti Biosciences Holdings, Inc. reported a first‑quarter 2026 net loss of $4.2 million, significantly narrower than $14.1 million a year earlier, helped by a $6.9 million gain from amending its Alameda lease.
Cash and cash equivalents were $8.9 million as of March 31, 2026, with operating cash outflow of $7.5 million for the quarter. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern, expecting current resources to fund operations only into the second quarter of 2026.
After quarter‑end, Senti agreed to a securities purchase arrangement for up to $40.0 million of senior secured convertible notes, with an initial $10.0 million tranche expected in May 2026, which would extend operations into the third quarter of 2026. The company remains a clinical‑stage biotech with an accumulated deficit of $362.8 million, continuing to invest in its SENTI‑202 program and gene circuit platform while relying on external financing, including an at‑the‑market equity program and related‑party funding.
Senti Biosciences (SNTI) filed its Q3 2025 10‑Q, reporting a net loss of $18.1 million for the quarter and $47.0 million for the nine months. Cash and cash equivalents were $12.2 million at September 30, 2025, down from $48.3 million at year‑end, and management concluded that substantial doubt exists about the company’s ability to continue as a going concern without additional financing.
Operating expenses were $16.9 million in Q3, driven by R&D $10.5 million and G&A $6.4 million. Net cash used in operating activities was $36.6 million for the nine months. The company also recorded a $3.3 million reversal of previously recognized sublease income tied to related‑party GeneFab after determining collectibility was not probable. As of quarter‑end, GeneFab owed $4.7 million in past‑due sublease rent; $1.0 million was received in October.
Senti received a default notice on its Alameda lease for ~$0.4 million of unpaid rent; discussions to cure are ongoing and the lease remains in place. The company converted 21,157 shares of Series A preferred into 21,157,000 common shares in March 2025. Shares outstanding were 26,290,838 as of October 31, 2025. CIRM grant receipts totaled $7.4 million to date, supporting the SENTI‑202 program.